SHUKRAPHAR54.00

Shukra Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
Returns
Return on Common Equity17.4232.16
Return on Assets5.8823.82
Return on Invested Capital13.2532.15
Margins
EBITDA Margin9.1226.02
Operating Margin5.9923.27
Incremental Operating Margin87.85
Pretax Margin7.5526.66
Net Income Margin7.4924.86
FCF Margin-2.25-9.33
Additional
Effective Tax Rate0.796.77
Dvd Payout Ratio1.650.38
Sustainable Growth Rate17.1332.04
Incremental Operating Margin %87.85
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.